Abstract: Disclosed herein is a therapeutics structure containing a motion element, an methotrexate (MTX), N—[N—[(S)-1,3-dicarboxypropyl]carbamoyl]-(S)-lysine (DCL), or UAMC-1110 ligand, and a plurality of drugs selected from the group consisting of camptothecin (CPT), paclitaxel (PTX), podophyllotoxin (PTOX), 7-Ethyl-10-hydroxycamptothecin (SN38), BMS1, BMS8, BMS27, BMS242, LY294002, PI3K-IN-20, and methotrexate (MTX).

Abstract: A transistor device may include a semiconductor structure including a channel layer and a barrier layer on the channel layer, wherein the barrier layer has a higher bandgap than the channel layer; a source contact and a drain contact on the barrier layer; a gate contact on the semiconductor structure between the source contact and the drain contact, the gate contact including a drain-side wing portion extending from a central portion of the gate contact; and a field plate on the semiconductor structure between the gate contact and the drain contact and laterally offset from the gate contact by a distance. The field plate may include a first wing portion extending from a central portion of the field plate.

Abstract: This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.

Abstract: Methods and systems for reducing electromagnetic interference in analog circuit of a control device for an augmented reality (AR) or virtual reality (VR) system are described. An analog circuit associated with the control device may include at least one amplifier and an analog-to-digital converter coupled to an amplifier by one or more electrical conductors. Electromagnetic interference induced in the one or more electrical conductors by an external AC magnetic field may be reduced using at least one component of the control device configured to reduce the electromagnetic interference.

Abstract: In accordance with various embodiments, described herein are systems and methods for enabling backup and recovery of cloud services (services) in a cloud computing environment (cloud environment). The techniques described herein can be used, for example, to facilitate restoration of a service that may have been originally provisioned as part of a user system/environment, within the cloud environment, and was subsequently lost due to accident deletion of the service, or cloud account termination. A service archive, created during a backup process, includes an archive file that contains the artifacts that were installed and/or created when the service was provisioned; and a metadata file that contains the current state information for the service when the backup was performed. During a recovery process, a lost service can be provisioned within the user system/environment, using the contents of the service archive, irrespective of whether the service itself still exists within the user system/environment.

Abstract: In accordance with various embodiments, described herein are systems and methods for enabling backup and recovery of cloud services (services) in a cloud computing environment (cloud environment). The techniques described herein can be used, for example, to facilitate restoration of a service that may have been originally provisioned as part of a user system/environment, within the cloud environment, and was subsequently lost due to accident deletion of the service, or cloud account termination. A service archive, created during a backup process, includes an archive file that contains the artifacts that were installed and/or created when the service was provisioned; and a metadata file that contains the current state information for the service when the backup was performed. During a recovery process, a lost service can be provisioned within the user system/environment, using the contents of the service archive, irrespective of whether the service itself still exists within the user system/environment.